中文Laos Vientiane-October 11, 2023-BigBear Pharma, a leading alchemon company focusing on development and commercial cancer innovation therapy,
announced today that three products has been approved by the Ministry of Health of Laos.
The approved drugs are:
Selpercatinib: Sell with the SEPADX brand name. Selpercatinib was approved for medical use in the United States in May 2020. Selpercatinib is the first therapy approved specifically for people with cancer and the RET gene alterations. Selpercatinib is a kinase inhibitor, meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing. Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing.
Entrectinib: Sell with the ENTREDX brand name. Entrectinib is an oral, selective tyrosine kinase inhibitor (TRKI) that targets patients with tropomyosin receptor kinase (NTRK) 1/2/3 or proto-oncogene tyrosine protein kinase 1 (ROS1) locally advanced or metastatic solid tumors. Entrectinib can pass through the blood-brain barrier, block the activity of TRKA/B/C and ROS1 protein kinases, and cause the death of cancer cells carrying ROS1 or NTRK gene fusion proteins. Entrectinib is effective in patients with both primary and metastatic central nervous system (CNS) tumors without adverse off-target activity.
Enasidenib: Sell with the ENASIDX brand name. Ensidipine is the first inhibitor of isocitrate dehydrogenase 2, which can effectively treat acute myeloid leukemia caused by mutations in this enzyme. It is also the only new drug for tumor metabolism therapy approved by the US Food and Drug Administration for this patient group.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.